At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomised phase 3 clinical trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage 4 non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.
